Institution
Marche Polytechnic University
Education•Ancona, Italy•
About: Marche Polytechnic University is a education organization based out in Ancona, Italy. It is known for research contribution in the topics: Population & Cancer. The organization has 5905 authors who have published 15769 publications receiving 382286 citations. The organization is also known as: Universitá Politecnica delle Marche & Universita Politecnica delle Marche.
Topics: Population, Cancer, Medicine, Context (language use), Prostate cancer
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The release of GF from the composites of chitosan-PRP and either nano-hydroxyapatite or tricalcium phosphate was highly beneficial for enhancing MSC proliferation and differentiation, thus qualifying chitOSan as an excellent vehicle.
182 citations
••
TL;DR: It is proposed that ECM should be considered as a crucial target for future therapeutics to control abnormal leiomyoma growth and associated clinical symptoms and the introduction of drugs that are specifically antifibrotic could be a good solution.
Abstract: Background Uterine leiomyoma (also known as fibroid or myoma) is the most common benign tumor of the uterus found in women of reproductive age. It is not usually fatal but can produce serious clinical symptoms, including excessive uterine bleeding, pelvic pain or pressure, infertility and pregnancy complications. Due to lack of effective medical treatments surgery has been a definitive choice for the management of this tumor. Objective and rationale Extracellular matrix (ECM) accumulation and remodeling are thought to be crucial for fibrotic diseases such as uterine leiomyoma. Indeed, ECM plays important role in forming the bulk structure of leiomyoma, and the ECM-rich rigid structure within these tumors is thought to be a cause of abnormal bleeding and pelvic pain. Therefore, a better understanding of ECM accumulation and remodeling is critical for developing new therapeutics for uterine leiomyoma. Search methods PubMed and Google Scholar were searched for all original and review articles/book chapters related to ECM and medical treatments of uterine leiomyoma published in English until May 2017. Outcomes This review discusses the involvement of ECM in leiomyoma pathogenesis as well as current and future medical treatments that target ECM directly or indirectly. Uterine leiomyoma is characterized by elevated levels of collagens, fibronectin, laminins and proteoglycans. They can induce the mechanotransduction process, such as activation of the integrin-Rho/p38 MAPK/ERK pathway, resulting in cellular responses that are involved in pathogenesis and altered bidirectional signaling between leiomyoma cells and the ECM. ECM accumulation is affected by growth factors (TGF-β, activin-A and PDGF), cytokines (TNF-α), steroid hormones (estrogen and progesterone) and microRNAs (miR-29 family, miR-200c and miR-93/106b). Among these, TGF-βs (1 and 3) and activin-A have been suggested as key players in the accumulation of excessive ECM (fibrosis) in leiomyoma. The presence of elevated levels of ECM and myofibroblasts in leiomyoma supports the fibrotic character of these tumors. Interestingly, ECM may serve as a reservoir of profibrotic growth factors and enhance their activity by increasing their stability and extending their duration of signaling. At present, several classes of compounds, including gonadotropin-releasing hormone (GnRH) agonist (leuprolide acetate), GnRH antagonist (cetrorelix acetate), selective progesterone receptor modulators (ulipristate acetate and asoprisnil), antiprogestin (mifepristone) and natural compounds like vitamin D and resveratrol have been studied as medical treatments that target ECM in uterine leiomyoma. Wider implications Although several types of drugs (mostly antiproliferative agents) are available for leiomyoma treatment, none of them were introduced specifically as antifibrotic agents. In light of its critical role in the process of fibrosis in leiomyoma, we propose that ECM should be considered as a crucial target for future therapeutics. Thus, the introduction of drugs that are specifically antifibrotic could be a good solution to control abnormal leiomyoma growth and associated clinical symptoms. The antifibrotic compounds can be introduced based on their ability to regulate ECM components and their receptors, as well as growth factors, cytokines, steroid hormones and their corresponding receptors and intracellular signaling pathways, as well as microRNAs, involved in ECM production in leiomyoma.
181 citations
••
TL;DR: In this article, the authors used Remotely Operated Vehicle (ROV) surveys to assess the extent of fishing impacts on rocky substrata on four offshore banks between 70 and 280m depth in the Mediterranean Sea.
181 citations
••
TL;DR: 129 miRNA tools that are being used in diverse areas of miRNA research are analyzed, to assist investigators in choosing the most appropriate tools for their needs.
Abstract: Recently, microRNAs (miRNAs) have emerged as important elements of gene regulatory networks. MiRNAs are endogenous single-stranded non-coding RNAs (~22-nt long) that regulate gene expression at the post-transcriptional level. Through pairing with mRNA, miRNAs can down-regulate gene expression by inhibiting translation or stimulating mRNA degradation. In some cases they can also up-regulate the expression of a target gene. MiRNAs influence a variety of cellular pathways that range from development to carcinogenesis. The involvement of miRNAs in several human diseases, particularly cancer, makes them potential diagnostic and prognostic biomarkers. Recent technological advances, especially high-throughput sequencing, have led to an exponential growth in the generation of miRNA-related data. A number of bioinformatic tools and databases have been devised to manage this growing body of data. We analyze 129 miRNA tools that are being used in diverse areas of miRNA research, to assist investigators in choosing the most appropriate tools for their needs.
181 citations
••
TL;DR: EM has a poor prognosis during the acute phase, despite a publication bias that could have led to an overestimation of mortality, and specific trials and multicenter registries are needed to provide evidence-based treatments to improve in-hospital outcome.
181 citations
Authors
Showing all 6013 results
Name | H-index | Papers | Citations |
---|---|---|---|
Jonathan I. Epstein | 138 | 1121 | 80975 |
Antoni Ribas | 132 | 660 | 99227 |
Francesco Fiori | 128 | 1032 | 76699 |
Claudio Franceschi | 120 | 856 | 59868 |
Robert E. Coleman | 103 | 724 | 49796 |
Carmine Zoccali | 99 | 813 | 36774 |
Massimo Falconi | 94 | 667 | 41966 |
Mario Plebani | 91 | 1329 | 43055 |
Roberto Danovaro | 84 | 415 | 23735 |
Rodolfo Montironi | 83 | 958 | 30957 |
Diego Centonze | 81 | 463 | 22857 |
Saverio Cinti | 78 | 256 | 32760 |
Michele Brignole | 76 | 399 | 26758 |
Jürgen P. Rabe | 76 | 391 | 20174 |
Jean-Jacques Body | 70 | 384 | 19608 |